Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Purpose
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Condition
- Breast Cancer
Eligibility
- Eligible Ages
- Over 40 Years
- Eligible Genders
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Patients must have newly diagnosed histologically proven invasive carcinoma of the breast with no evidence of metastases. - Patients must have been treated by BCS or mastectomy. - Patients treated by BCS or mastectomy and axillary dissection must have 1-3 positive axillary nodes (macrometastases, > 2 mm). - Patients treated by BCS and SLNB alone must have only 1-2 positive axillary nodes (macrometastases, > 2 mm). - Patients treated by mastectomy and SLNB alone must have only 1 positive axillary node (macrometastases, > 2 mm). - Patients must be ER ≥ 1% and HER2 negative on local testing - Patients must have an Oncotype DX recurrence score <18 - Patient must consent to provision of, and investigator(s) must confirm access to and agree to submit to the CCTG Central Tumour Bank, a representative formalin fixed paraffin block of tumour tissue in order that the specific correlative marker assays described in the protocol may be conducted - Patient must consent to provision of samples of blood in order that the specific correlative marker assays described in the protocol may be conducted. - Patients must have had endocrine therapy initiated or planned for ≥ 5 years. Endocrine therapy can be given concurrently or following RT. - Patients may or may not have had adjuvant chemotherapy. - RT must be administered within 12 weeks of definitive surgery if the patient is not treated with chemotherapy. If adjuvant chemotherapy is given, RT must begin within 2-8 weeks after the last dose. - Patient's ECOG performance status must be 0, 1 or 2. - Patient's age must be ≥ 40 years. - Patient's life expectancy is ≥10 years - For the first 736 eligible English or French-speaking subjects who have agreed to optional questionnaire completion: Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life, health utilities and lost productivity questionnaires in either English or French - Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements - Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up. - In accordance with CCTG policy, protocol treatment is to begin within 3 weeks of patient randomization. - Women of childbearing potential must have agreed to use an effective contraceptive method. A woman is considered to be of "childbearing potential" if she has had menses at any time in the preceding 12 consecutive months.
Exclusion Criteria
- Patients with nodal disease limited to micrometastases (pN1Mi, > 0.2 mm and ≤ 2 mm) or isolated tumour cells (pN0i+ < 0.2 mm). - Any prior history, not including the index cancer, of ipsilateral invasive breast cancer or ipsilateral DCIS treated with radiation therapy. (Patients with synchronous or previous ipsilateral LCIS are eligible.) - Synchronous or previous contralateral invasive breast cancer. (Patients with contralateral DCIS not treated with radiation are eligible.) - History of non-breast malignancies except adequately treated non-melanoma skin cancers, in situ cancers treated by local excision or other cancers curatively treated with no evidence of disease for ≥ 5 years. - Patients with pT3 or pT4 disease. - Patients who are pregnant. - Patients that have had prior ipsilateral chestwall/thoracic radiation. - Patients treated with neoadjuvant chemo or endocrine therapy for breast cancer. - Patients with serious non-malignant disease (e.g. cardiovascular, scleroderma etc.) which would preclude RT. - Patients with any serious active or co-morbid medical conditions, laboratory abnormality, psychiatric illness, active or uncontrolled infections, or serious illnesses or medical conditions that would prevent the patient from participating or to be managed according to the protocol (according to investigator's decision).
Study Design
- Phase
- N/A
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Active Comparator No Regional Radiotherapy |
A. Whole Breast Irradiation (WBI) following BCS or; B. No Radiotherapy (RT) following mastectomy |
|
Active Comparator Regional Radiotherapy |
A. WBI plus RT to the regional nodes (supraclavicular, non-dissected axillary, and internal mammary) following BCS or; B. RT to the chestwall and regional nodes (supraclavicular, non-dissected axillary, and internal mammary) following mastectomy |
|
Recruiting Locations
Fairbanks, Alaska 99701
Tucson, Arizona 85704
Site Public Contact
520-694-8900
Tucson, Arizona 85719
Site Public Contact
800-327-2873
Little Rock, Arkansas 72205
Site Public Contact
501-686-8274
Anaheim, California 92806
Berkeley, California 94704
Duarte, California 91010
Dublin, California 94568
Site Public Contact
877-642-4691
Fresno, California 93720
Los Angeles, California 90027
Los Angeles, California 90033
Site Public Contact
323-865-0451
Oakland, California 94611
Orange, California 92868
Site Public Contact
714-734-6220
Rancho Cordova, California 95670
Rohnert Park, California 94928
Roseville, California 95678
Santa Clara, California 95051
South Pasadena, California 91030
South San Francisco, California 94080
Vallejo, California 94589
Aurora, Colorado 80045
Site Public Contact
720-848-0650
Colorado Springs, Colorado 80907
Colorado Springs, Colorado 80909
Site Public Contact
719-365-2406
Colorado Springs, Colorado 80920
Site Public Contact
719-364-6700
Fort Collins, Colorado 80524
Site Public Contact
970-297-6150
Greeley, Colorado 80631
Littleton, Colorado 80122
Loveland, Colorado 80539
Wheat Ridge, Colorado 80033
Guilford, Connecticut 06437
Hamden, Connecticut 06518
New Haven, Connecticut 06520
Trumbull, Connecticut 06611
Waterford, Connecticut 06385
Newark, Delaware 19713
Newark, Delaware 19718
Washington, District of Columbia 20007
Site Public Contact
202-444-2223
Washington, District of Columbia 20010
Site Public Contact
202-877-8839
Clearwater, Florida 33756
Site Public Contact
855-314-8646
Coral Gables, Florida 33146
Site Public Contact
305-243-2647
Deerfield Beach, Florida 33442
Site Public Contact
305-243-2647
Hollywood, Florida 33021
Jacksonville, Florida 32224-9980
Site Public Contact
855-776-0015
Miami, Florida 33136
Site Public Contact
305-243-2647
Orlando, Florida 32806
Pembroke Pines, Florida 33028
Site Public Contact
954-265-4325
Saint Petersburg, Florida 33705
Tampa, Florida 33607
Tampa, Florida 33612
Weston, Florida 33331
Savannah, Georgia 31405
Boise, Idaho 83706
Chicago, Illinois 60611
Chicago, Illinois 60612
Chicago, Illinois 60612
Site Public Contact
312-355-3046
Chicago, Illinois 60625
Site Public Contact
773-878-8200
Chicago, Illinois 60657
Site Public Contact
773-296-5360
Decatur, Illinois 62526
Effingham, Illinois 62401
Geneva, Illinois 60134
Lake Forest, Illinois 60045
Maywood, Illinois 60153
Site Public Contact
708-226-4357
Peoria, Illinois 61637
Rockford, Illinois 61114
Springfield, Illinois 62781
Site Public Contact
217-788-3528
Urbana, Illinois 61801
Warrenville, Illinois 60555
Avon, Indiana 46123
Carmel, Indiana 46032
Fishers, Indiana 46037
Site Public Contact
317-356-2422
Indianapolis, Indiana 46202
Indianapolis, Indiana 46202
Indianapolis, Indiana 46219
Indianapolis, Indiana 46227
Indianapolis, Indiana 46256
Muncie, Indiana 47303
Site Public Contact
765-751-5850
Clive, Iowa 50325
Creston, Iowa 50801
Des Moines, Iowa 50309
Site Public Contact
515-241-6727
Des Moines, Iowa 50314
Kansas City, Kansas 66160
Overland Park, Kansas 66210
Wichita, Kansas 67214
Edgewood, Kentucky 41017
Lexington, Kentucky 40536
Site Public Contact
859-257-3379
Louisville, Kentucky 40202
Site Public Contact
502-562-3429
Bath, Maine 04530
Brewer, Maine 04412
Site Public Contact
800-987-3005
Portland, Maine 04102
Site Public Contact
207-885-7565
Sanford, Maine 04073
Site Public Contact
207-459-1600
Scarborough, Maine 04074
Annapolis, Maryland 21401
Baltimore, Maryland 21204
Site Public Contact
443-849-3706
Baltimore, Maryland 21237
Site Public Contact
443-777-7364
Boston, Massachusetts 02215
Site Public Contact
617-667-9925
Burlington, Massachusetts 01805
Lowell, Massachusetts 01854
Springfield, Massachusetts 01199
Ann Arbor, Michigan 48109
Site Public Contact
800-865-1125
Dearborn, Michigan 48124
Site Public Contact
248-551-7695
Farmington Hills, Michigan 48336
Site Public Contact
248-551-7695
Grand Rapids, Michigan 49503
Kalamazoo, Michigan 49007
Muskegon, Michigan 49444
Novi, Michigan 48374
Royal Oak, Michigan 48073
Site Public Contact
248-551-7695
Southfield, Michigan 48075
Traverse City, Michigan 49684
Troy, Michigan 48085
Site Public Contact
248-551-7695
Wyoming, Michigan 49519
Bemidji, Minnesota 56601
Minneapolis, Minnesota 55415
Southhaven, Mississippi 38671
Cape Girardeau, Missouri 63703
Columbia, Missouri 65212
Site Public Contact
573-882-7440
Kansas City, Missouri 64154
Lee's Summit, Missouri 64064
Saint Louis, Missouri 63131
Site Public Contact
314-996-5569
Billings, Montana 59101
Butte, Montana 59701
Site Public Contact
406-723-2621
Great Falls, Montana 59405
Omaha, Nebraska 68198
Concord, New Hampshire 03301
Site Public Contact
603-224-2556
Manchester, New Hampshire 03103
Site Public Contact
800-339-6484
Basking Ridge, New Jersey 07920
Site Public Contact
212-639-7592
Englewood, New Jersey 07631
Site Public Contact
201-894-3456
Hamilton, New Jersey 08690
Site Public Contact
609-631-6946
Middletown, New Jersey 07748
Site Public Contact
212-639-7592
Montvale, New Jersey 07645
Site Public Contact
212-639-7592
New Brunswick, New Jersey 08903
Site Public Contact
732-235-7356
Sewell, New Jersey 08080
Somerville, New Jersey 08876
Albuquerque, New Mexico 87102
Albuquerque, New Mexico 87109
Albuquerque, New Mexico 87109
Las Cruces, New Mexico 88011
Bronx, New York 10461
Bronx, New York 10467
Commack, New York 11725
Site Public Contact
212-639-7592
Cooperstown, New York 13326
Harrison, New York 10604
Site Public Contact
212-639-7592
New York, New York 10003
New York, New York 10011
New York, New York 10016
New York, New York 10029
New York, New York 10032
New York, New York 10065
Site Public Contact
212-639-7592
Stony Brook, New York 11794
Site Public Contact
800-862-2215
Uniondale, New York 11553
Site Public Contact
212-639-7592
Asheville, North Carolina 28801
Asheville, North Carolina 28816
Durham, North Carolina 27710
Site Public Contact
888-275-3853
Gastonia, North Carolina 28054
Bismarck, North Dakota 58501
Grand Forks, North Dakota 58201
Site Public Contact
701-780-6520
Akron, Ohio 44307
Beachwood, Ohio 44122
Canton, Ohio 44708
Site Public Contact
888-293-4673
Canton, Ohio 44710
Chardon, Ohio 44024
Cleveland, Ohio 44106
Columbus, Ohio 43210
Columbus, Ohio 43214
Columbus, Ohio 43219
Elyria, Ohio 44035
Mentor, Ohio 44060
Middleburg Heights, Ohio 44130
Parma, Ohio 44129
Ravenna, Ohio 44266
Sandusky, Ohio 44870
Wadsworth, Ohio 44281
Westlake, Ohio 44145
Westlake, Ohio 44145
Oklahoma City, Oklahoma 73104
Corvallis, Oregon 97330
Bryn Mawr, Pennsylvania 19010
Chadds Ford, Pennsylvania 19317
Erie, Pennsylvania 16544
Site Public Contact
814-452-5000
Jefferson Hills, Pennsylvania 15025
Lancaster, Pennsylvania 17601
Site Public Contact
717-544-0511
Lancaster, Pennsylvania 17602
Site Public Contact
717-544-5511
Media, Pennsylvania 19063
Monroeville, Pennsylvania 15146
Site Public Contact
412-858-7746
Newtown Square, Pennsylvania 19073
Paoli, Pennsylvania 19301
Philadelphia, Pennsylvania 19107
Site Public Contact
215-955-6084
Pittsburgh, Pennsylvania 15212
Site Public Contact
877-284-2000
Pittsburgh, Pennsylvania 15224
Site Public Contact
412-578-5000
Reading, Pennsylvania 19605
West Reading, Pennsylvania 19611
Site Public Contact
610-988-9323
Wynnewood, Pennsylvania 19096
Providence, Rhode Island 02905
Site Public Contact
401-274-1122
Boiling Springs, South Carolina 29316
Greenville, South Carolina 29605
Greenville, South Carolina 29607
Greenville, South Carolina 29615
Greer, South Carolina 29650
Seneca, South Carolina 29672
West Columbia, South Carolina 29169
Sioux Falls, South Dakota 57117-5134
Memphis, Tennessee 38120
Conroe, Texas 77384
Dallas, Texas 75235
Dallas, Texas 75390
Houston, Texas 77030
Houston, Texas 77079
Laredo, Texas 78041
Site Public Contact
956-523-2650
League City, Texas 77573
San Antonio, Texas 78229
Sugar Land, Texas 77478
Farmington, Utah 84025
Salt Lake City, Utah 84106
Salt Lake City, Utah 84112
South Jordan, Utah 84009
Burlington, Vermont 05401
Fishersville, Virginia 22939
Site Public Contact
540-332-5960
Morgantown, West Virginia 26506
Antigo, Wisconsin 54409
Appleton, Wisconsin 54911
Eau Claire, Wisconsin 54701
Grafton, Wisconsin 53024
Green Bay, Wisconsin 54301
Green Bay, Wisconsin 54303
Green Bay, Wisconsin 54311
Johnson Creek, Wisconsin 53038
Kenosha, Wisconsin 53142
Madison, Wisconsin 53792
Site Public Contact
800-622-8922
Marinette, Wisconsin 54143
Marshfield, Wisconsin 54449
Milwaukee, Wisconsin 53215
Milwaukee, Wisconsin 53233
Minocqua, Wisconsin 54548
Oshkosh, Wisconsin 54904
Rice Lake, Wisconsin 54868
Sheboygan, Wisconsin 53081
Sheboygan, Wisconsin 53081
Stevens Point, Wisconsin 54482
Sturgeon Bay, Wisconsin 54235-1495
Summit, Wisconsin 53066
Two Rivers, Wisconsin 54241
Wausau, Wisconsin 54401
Site Public Contact
877-405-6866
West Allis, Wisconsin 53227
Weston, Wisconsin 54476
Wisconsin Rapids, Wisconsin 54494
Site Public Contact
715-422-7718
More Details
- NCT ID
- NCT03488693
- Status
- Recruiting
- Sponsor
- Canadian Cancer Trials Group
Detailed Description
Women with node positive breast cancer normally will receive endocrine therapy and some may receive chemotherapy to help prevent the cancer from coming back. Many women will also receive radiotherapy to the whole breast/chest area and the surrounding lymph glands (called regional radiotherapy). No one really knows whether patients with low risk breast cancer need to receive regional radiotherapy. Some women may be getting regional radiotherapy who do not need it. These women may be exposed to the side effects of their treatment without benefit.